NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)vsRevolution Medicines Inc (RVMD)
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
$31.52
-3.52%
HEALTHCARE · Cap: $3.55B
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
NewAmsterdam Pharma Company N.V. Ordinary Shares generates 2941% more annual revenue ($22.57M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
NAMS
Avoid24
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
2.1% revenue growth
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NAMS
The strongest argument for NAMS centers on Debt/Equity, Altman Z-Score.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : NAMS
The primary concerns for NAMS are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
NAMS is growing revenue faster at 2.1% — sustainability is the question.
NAMS generates stronger free cash flow (-31M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NAMS scores higher overall (24/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NewAmsterdam Pharma Company N.V. Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
NewAmsterdam Pharma Company N.V. is a cutting-edge biotechnology firm focused on creating innovative therapies for cardiometabolic diseases, leveraging its proprietary technology platform to address significant unmet medical needs. The company possesses a robust clinical development pipeline, underscored by its commitment to advancing treatment paradigms in this critical area of healthcare. With an experienced leadership team and a clear strategic vision for growth, NewAmsterdam presents a compelling investment opportunity for those seeking to be part of transformative healthcare solutions aimed at enhancing patient outcomes.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?